CTLA4 and melanoma: Translational challenges for DAT include model-specific efficacy differences: it enhances anti-CTLA-4 efficacy in B16-OVA melanoma (42) but fails to augment the abscopal effect in MC38 colon adenocarcinoma (197), attributed to MC38’s low immunogenicity and reduced IFN-I responsiveness—highlighting the need for clinical patient stratification by tumor IFN-I gene signatures (e.g., OAS2/Mx2 expression, 165).